Background: There has been a surge in high-level studies investigating platelet-rich plasma (PRP) for tendon and ligament injuries. A number of meta-analyses have been published, but few studies have focused exclusively on tendon and ligament injuries.
by PRP have been shown to promote cell recruitment, proliferation, and angiogenesis. 26 It has also been suggested that PRP may induce a transient inflammatory event that triggers a regenerative response. 32 Other groups have hypothesized that PRP may have beneficial immunomodulatory effects on tenocytes. 3 Multiple meta-analyses have been published on PRP use for tendon or ligament injuries. 2, 72, 80, 89, 91 The majority of these studies have focused exclusively on rotator cuff healing or include low-powered studies, which limit their clinical utility. Previous groups have attempted similar reviews that focused exclusively on tendon/ligament injuries, 53, 76, 89 but these reviews were limited by a scarcity of high-level evidence publications when they were published. Additionally, while previous reviews such as those by Cai et al 8 and Warth et al 84 analyzed similar datasets, they report contrasting results and conclusions. Within studies that analyzed data from multiple outcome measures, PRP has been shown to be efficacious by some outcome scales and not others. For instance, a meta-analysis on PRP for rotator cuff healing by Yang et al 88 found that as a whole, PRP significantly improved Constant and visual analog scale (VAS) scores over the control, but there was no significant difference in University of California, Los Angeles (UCLA) shoulder scores or retear rates.
The comparative clinical efficacy of PRP, placebo (saline), autologous whole blood, dry needling, and corticosteroids for ligament and tendon injuries is unclear and controversial. Studies using animal models, for example, have not conclusively shown that PRP affects tendon repair, which is consistent with the contradictory outcomes of the clinical use of PRP for managing tendon injuries. 56 However, despite a lack of agreement within the literature regarding the beneficial effects of PRP, there has been a surge in both clinical use and randomized controlled studies. 67 The recent increase in high-level randomized controlled studies investigating the clinical efficacy of PRP prompted our systematic review and meta-analysis of the literature. This is the first study to synthesize data exclusively from level 1 randomized controlled clinical trials for ligament and tendon injuries. The goal of this study was to provide clinicians with an overview of the currently available data on PRP for tendon and ligament injuries. The clinical outcome being evaluated emphasizes PRP's efficacy in reducing pain.
METHODS

Search Methods for the Identification of Studies
This study followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and the PRISMA-IPD statement. 51, 74 A comprehensive search of the literature was carried out in April 2017 using electronic databases PubMed, MEDLINE, and the Cochrane Library (Figure 1 ). Two authors (X.C. and I.A.J.) independently performed the initial screening and study selection. Any disagreements were resolved by a discussion under the guidance of a third reviewer (C.T.V.).
The search terms used were ''PRP OR platelet-rich plasma AND tendon OR ligament OR tendinopathy.'' This yielded 4907 results after duplicates were removed. These results were filtered to only include ''randomized control trial'' and ''human'' species, leaving 63 results. Irrelevant and non-English articles were further excluded, leaving 53 full-text articles to be assessed for eligibility.
Of the 53 articles reviewed, 18 articles were excluded because they did not meet the inclusion criteria (detailed below). Two articles were added from bibliographies, resulting in 37 articles for qualitative synthesis. Of the 37 articles available for qualitative analysis, 2 sets of articles were combined because they used the same study population. A total of 21 studies were available for metaanalysis. A repeat search was performed in June 2017 and did not yield any new studies for inclusion.
Inclusion Criteria
Level 1 evidence studies, as defined by the Oxford Centre for Evidence-Based Medicine, that reported clinical outcomes for a PRP injection and platelet-rich fibrin matrix were considered for inclusion. Only full-length articles published in English were included. No studies were excluded based on follow-up time, although most studies followed patients clinically for at least 6 months. The number of injections, injection needle gauge, injection location, PRP concentration, PRP preparation method, PRP dosage, and usage of activating factors were recorded but not used as bases of inclusion/exclusion. Saline injection, dry needling, autologous whole blood injection, and corticosteroid injection were deemed appropriate controls. Basic science ex vivo and in vivo studies, animal studies, letters to the editor, editorials, personal correspondence, study protocols, levels 2 to 5 evidence, and studies investigating PRP usage in periodontal therapy were excluded.
Quantitative Analysis
The outcome of VAS pain scores was categorized as baseline, short term (up to 6.5 months' follow-up), and long term (1-year follow-up). When studies did not report the SD, they were calculated from the standard error or 95% CI. The SD calculated from the 95% CI used critical values from the t distribution because of the small sample size. In cases where the SD was not reported, or the median (range/ interquartile range) was reported, the authors were contacted via email to obtain the raw data. If the authors did not respond, the mean was calculated from the median and interquartile range as suggested by Wan et al, 82 and the SD was calculated using the Cochrane method. 31 VAS scores that were reported on a 0-to-100 scale were converted to a 0-to-10 scale to be consistent across the studies.
The weighted mean differences (WMDs) with 95% CIs were calculated for the continuous outcome of VAS scores for each study. Because the VAS was the only outcome of interest, and the unit of measurement was the same across studies, the mean difference was not standardized. A random-effects model was used because it was expected that there would be some variability across studies and under the assumption that the true effect would not be the same across all the studies.
Meta-analysis was performed by time subgroups (baseline, short term, and long term) as well as overall to determine the efficacy of PRP versus control on VAS pain scores. Subgroups based on injury (rotator cuff, tendinopathy, anterior cruciate ligament [ACL] , and lateral epicondylitis) were evaluated at each time point to determine if there was heterogeneity of PRP efficacy by pathological condition. The outputs from the forest plots were used to assess heterogeneity. The I 2 test was used to determine heterogeneity based on the thresholds reported in the Cochrane Handbook for Systematic Reviews of Interventions 31 : 0%-40% may not be important, 30%-60% may represent moderate heterogeneity, 50%-90% may represent substantial heterogeneity, and 75%-100% may represent considerable heterogeneity. To evaluate possible reasons for heterogeneity, meta-regression was conducted using the baseline difference in PRP versus control and pathological condition as possible explanatory factors; a permutation test approach was used to calculate the P values for meta-regression. Funnel plots were generated to visually assess asymmetry and potential publication bias, along with the Egger test. Sensitivity analysis was performed to evaluate the effect of potential outliers by removing studies one at a time. All analyses were performed using STATA version 14.2 (StataCorp).
RESULTS
Overview
Thirty-seven randomized controlled studies reporting clinical efficacy data on PRP for tendon or ligament injuries were included in this review. Five of these studies used the same dataset, leaving 34 unique study populations (Table 1) . Four authors were contacted to solicit missing information, and 2 responded with usable raw data. Six different injury subgroups were identified: rotator cuff injury, lateral epicondylitis, patellar tendinopathy, Achilles tendinopathy, ACL injury, and hamstring tendinopathy. The majority of studies (70.3%) investigated rotator cuff injuries or lateral epicondylitis. Eleven different controls were used, with approximately half of the studies (45.95%) using surgical repair without additional treatment as a control. No study reported severe adverse events.
There was extensive variability in the way that PRP was prepared (Table 1) . PRP injection procedures also varied widely. For example, 18 different PRP kits were used, and 7 studies used methods that did not utilize or describe the utilization of a specific kit. The most commonly used kits were the GPS II/III system (Biomet Biologics; 9 studies) and the Autologous Conditioned Plasma system (Arthrex; 4 studies), which together made up 35.1% of the included studies. Of the 37 studies included in this review, 19 did not activate PRP. All but 3 of the 18 studies that did include an activating agent used some form of calcium (CaCl 2 , calcium gluconate, or CaCl 2 and thrombin) to activate PRP. Two studies used thrombin alone, and 1 study used type I collagen. Few studies attempted to quantify platelets (40.5%) or leukocytes (24.3%), but the majority reported the volume of the PRP injection or gel ( Table  2 ). The calculation of the mean platelet concentration excludes values from Vetrano et al 81 because of the reported platelet concentration being an extreme outlier (1,000,000-fold higher than the next highest reported concentration). The authors could not be reached for clarification.
There was extensive heterogeneity in the studies included in this review. Studies were conducted across 17 unique countries and included the geographic regions of Europe (22 studies), Asia (9 studies), North America (3 studies), South America (2 studies), and Australia (1 study) (see Table 1 ). The mean patient age ranged from 23 to 66 years, and the female-to-male ratio of study participants ranged from 0 to 4.67. There was considerable heterogeneity in female-to-male ratios, which varied by country and by individual study. The mean participant age also varied greatly across studies. The 3 highest mean ages among all studies were 66, 63, and 62 years, while the 3 lowest mean ages were 23, 24, and 26 years.
There was also a variety of clinical outcome measures used. A number of body area-specific scores were reported, including the Shoulder Pain and Disability Index, PatientRated Tennis Elbow Evaluation, and International Knee Documentation Committee score. Even among studies investigating the same injury, different injury-specific clinical outcomes were reported. For example, of the 14 studies investigating PRP for rotator cuff injuries, 8 studies used the Constant score, 7 studies used the UCLA score, 6 studies used the Simple Shoulder Test (SST), 2 studies used the Oxford Shoulder Score (OSS), and 1 study used the Western Ontario Rotator Cuff Index (WORC).
Quantitative Analysis of Studies Reporting the VAS Score
A total of 21 studies were included in the meta-analysis evaluating the efficacy of PRP versus various controls with respect to pain (VAS) for tendon and ligament injuries. VAS scores from 21 of the 37 studies included in this review were available at baseline. Seventeen studies reported short-term VAS data, and 14 studies reported long-term VAS data (Table 3 ). There was no significant difference in VAS scores between PRP and control at baseline. Figure A1 , available in the online version of this article). Substantial heterogeneity was reported at baseline (I 2 = 72.0%; P \ .01), short-term follow-up (I 2 = 72.5%; P \ .01), long-term followup (I 2 = 76.1%; P \ .01), and overall (I 2 = 75.8%; P \ .01). To further explore if the heterogeneity could be explained by the tendon/ligament injury, injury subgroups (rotator cuff, tendinopathy, ACL, and lateral epicondylitis) were assessed at each time point. At baseline, the mean VAS pain score for the rotator cuff, tendinopathy, and lateral epicondylitis subgroups did not differ between PRP and control. However, patients with ACL injuries who received PRP treatment reported significantly less pain at baseline than controls (WMD, -1.84; 95% CI, -2.51 to -1.17; P \ .01) (see Appendix Figure A2 , available online). Further investigation will be needed to determine if the difference had to do with how the patients were randomized or if there were other study-related factors leading to these results in studies treating ACL injuries. Within each injury subgroup, only rotator cuff injuries showed significant heterogeneity (I 2 = 59.6%; P = .02), while the other subgroups showed little to moderate heterogeneity that was not significant.
Short-term Follow-up. For short-term (2-6.5 months) follow-up, there was no difference in pain between PRPtreated and control groups for patients with tendinopathy injuries. Rotator cuff injuries (WMD, -0.45; 95% CI, -0.75 to -0.15; P \ .01), ACL injuries (WMD, -1.26; 95% CI, -2.33 to -0.19; P = .02), and lateral epicondylitis (WMD, -1.14; 95% CI, -1.85 to -0.43; P \ .01) showed a decrease in pain for the PRP group compared with the control group (Figure 2) . Overall, the pooled results showed a significant difference in pain between PRP and control at short-term follow-up (WMD, -0.72; 95% CI, -1.10 to -0.34; P \ .01). Because there were very few studies reported for tendinopathy and ACL injuries, more data are needed to determine if the results from other similar studies are consistent with these findings. At short-term follow-up, there was substantial heterogeneity (I 2 = 72.5%; P \ .01) between the studies overall. There was also substantial heterogeneity at short-term follow-up in the tendinopathy (I 2 = 91.7%; P \ .01) and lateral epicondylitis (I 2 = 75.1%; P \ .01) subgroups. Long-term Follow-up. Overall, long-term follow-up results showed less pain in the PRP group compared with the control group (WMD: -0.84; 95% CI, -1.23 to -0.44; P \ .01). Looking at injury subgroups, patients with rotator cuff injuries (WMD, -0.53; 95% CI, -0.98 to -0.09; P = .02), lateral epicondylitis (WMD, -1.39; 95% CI, -2.49 to -0.29; P = .01), and tendinopathy (WMD, -1.70; 95% CI, -2.90 to -0.50; P \ .01) reported less pain when treated with PRP; PRP did not affect pain in the ACL injury subgroup (Figure 3 ). There were only 1 to 2 ACL and tendinopathy studies available for meta-analysis at long-term follow-up, so more data would need to be collected and analyzed to determine if these results remain consistent. There was considerable heterogeneity reported for lateral epicondylitis (I 2 = 79.3%; P \ .01) and for the overall studies at long-term follow-up (I 2 = 76.1%; P \ .01). To determine if the different injuries were contributing to the heterogeneity, meta-regression using a permutationbased test approach was used. After adjusting for whether there was a baseline difference in PRP versus control, pathological condition did not appear to contribute to heterogeneity (short term: P = .39; long term: P = .29).
Publication bias was assessed including all the data collected using a funnel plot (see Appendix Figure A3 , available online). The funnel plot appeared to be asymmetric, with some missingness at the lower right portion of the plot suggesting possible publication bias, along with outliers, especially to the left. The outliers were predominantly from studies in which the injury of interest was the ACL or lateral epicondylitis (Figure 4 ). When the Egger test was performed, there was an indication of small study effects (P \ .01) most likely caused by heterogeneity. Appendix Figure  A4 (available online) shows the overall funnel plot with injury subgroup indicators. Separate funnel plots were produced for the time subgroups that showed that there were some data missing at the lower right portion of the funnel plot and some outliers (see Appendix Figures A5A, A6A , and A7A, available online). The Egger test indicated that there was a small study effect for the long-term results (P \ .01). When looking at each time subgroup by injury, it was evident that outliers were predominately from the ACL injury subgroup at baseline and the lateral epicondylitis subgroup at short-term and long-term follow-up, suggesting possible heterogeneity due to pathological condition (see Appendix Figures A5B, A6B , and A7B, available online). A sensitivity analysis was performed removing potential outliers observed from the funnel plots for all the data collected. The baseline time point became significant when the studies by Peerbooms et al 60 (WMD, -0.33; 95% CI, -0.64 to -0.03; P = .03), Vetrano et al 81 (WMD, -0.31; 95% CI, -0.61 to -0.01; P = .04), Dragoo et al 24 (WMD, -0.32; 95% CI, -0.62 to -0.02; P = .04), and Wang et al 83 (WMD, -0.34; 95% CI, -0.63 to -0.04; P = .03) were removed one at a time. For short-term follow-up, when the Dragoo et al 24 study was removed, the tendinopathy subgroup became significant (WMD, -1.50; 95% CI, -2.72 to -0.28; P = .02), although the overall short-term results did not change. For long-term follow-up, lateral epicondylitis became nonsignificant when the Behera et al 6 or the Peerbooms et al 60 study was removed. All other outliers did not change the results for either the injury subgroups or overall results. None of these studies were removed from the final analysis, as there was no indication of error in the data reported, and they were relevant to the study.
DISCUSSION
Our review of the literature suggests that PRP for tendon and ligament injuries is safe; of the 1937 unique patients treated with PRP, no significant adverse events were reported. These results are in agreement with the existing literature, which concludes that PRP is a safe treatment option for injured musculoskeletal tissues. 49 Our meta-analysis of VAS scores showed significant improvement in PRP-treated groups compared with control groups in patients with tendon and ligament injuries Figure 2 . Forest plot of the weighted mean difference (WMD) between platelet-rich plasma (PRP) and control by injury subgroup at short-term follow-up.
at both short-term and long-term follow-ups. These findings contrast those of Moraes et al, 53 who reported no significant difference in pain reduction between patients treated with PRP versus alternative therapies. Moraes et al, 53 however, only qualitatively analyzed a few studies, many of which were not of level 1 evidence. Additionally, we found evidence that PRP significantly decreased pain compared with control treatments in patients with rotator cuff and lateral epicondylitis injuries. Our findings on rotator cuff healing contrast the results reported in a metaanalysis by Warth et al, 84 which found no significant difference in VAS score improvement between PRP-treated patients and the control population with rotator cuff tears. Our findings on lateral epicondylitis are in agreement with a recent meta-analysis by Arirachakaran et al, 5 which found that PRP treatment led to significantly improved VAS scores compared with alternative treatments in patients with lateral epicondylitis.
We chose to review the efficacy of PRP for both tendons and ligaments because the tissues are morphologically similar. This approach allowed us to include a large number of level 1 studies in this review but also has several limitations. While both tendons and ligaments are classified as dense, regular connective tissue and the 2 tissue types share a number of similarities, 23, 28, 79 there are inherent biological differences between tendons and ligaments that should be considered. One of the main differences between tendons and ligaments is that ligaments are more metabolically active than tendons.
1 Ligaments also have a higher DNA content, have more cellular nuclei, have greater amounts of reducible cross-links, and are composed of more type III collagen by percentage. Even among different types of tendons, there are clinically and biologically important differences. 40, 56, 70 For example, the successful repair of short tendons (eg, rotator cuff tendons) generally depends on tendon-to-bone integration, whereas the effective repair of longer tendons (eg, flexor tendons) usually depends more on the prevention of repair-site gapping and maintenance of tendon gliding. 40 Nevertheless, we believe that our approach is reasonable, given the lack of standardization in both the literature and the treatment itself.
Common weaknesses of the studies included in this review were potential bias caused by small study effects, reporting bias, and lack of blinding. Twelve studies included in the quantitative analysis were single blind or not blinded at all, which may have contributed to bias. Data collected using a funnel plot showed asymmetry, which suggests publication bias, and the Egger test found evidence of small study effects. Overall, these biases are most likely caused by heterogeneity in study populations such as mean age, sex ratio, and other study-related factors. Differences in injuries as a whole were not found to contribute significantly to heterogeneity, which might be a result of not having enough studies, especially for the ACL and tendinopathy subgroups. At baseline, outliers on the funnel plot were predominately from ACL injury studies. This suggests that heterogeneity may be caused by ACL injury studies, including the articles published by Seijas et al 68 and Cervellin et al. 12 The VAS scores of PRP-treated patients in both of these studies were significantly (P \ .05) lower at baseline than those in the control group. Further analysis with more data is needed to determine if pathological condition or other study-related factors could have contributed to the heterogeneity in this study.
This review has several weaknesses. First, heterogeneity in the way that clinical outcomes were measured limited our ability to make quantitative comparisons. To accommodate for the heterogeneity, we focused exclusively on VAS scores when evaluating outcomes quantitatively. Additionally, 16 of the studies that were included in this review only blinded patients or did not blind at all. Several studies experienced some patient loss to follow-up. However, the percentage lost to follow-up was small (\5% for most studies), so this factor is unlikely to have skewed the overall results. Another common weakness was the lack of clarification regarding the composition of PRP. No article quantified the exact composition of the PRP ''drug.'' While growth factors (PDGF, VEGF, EGF, FGF, 90 TGF-beta) within patients' autologous whole blood do not vary significantly with age or sex, and the concentration of growth factors has not been strongly correlated with platelet count, the method of PRP preparation greatly affects cytokine concentrations. 47, 57, 86, 87 Given that most studies prepare PRP using different PRP kits, there is unknown and unquantified variability in the platelet count and growth factor concentration. To resolve the heterogeneity within PRP formulations, studies have attempted to establish classification systems for PRP. 21, 22, 50 For example, DeLong et al 20 created the PAW system, which relies on absolute platelet count, manner of platelet activation, and presence or absence of white blood cells (WBCs). However, the lack of reported information on requisite factors, such as platelet count, precludes the categorization of many studies. Without biochemical analysis, there is no way to determine how PRP composition affects clinical outcomes and makes comparing different studies less reliable. 7 Finally, in addition to the controllable variability between studies, the inherent variability of PRP itself cannot be overlooked. Because PRP is a pointof-care autologous therapy, no 2 patients are receiving exactly the same treatment. 87 In addition to platelets, PRP contains varying levels of leukocytes (monocytes, basophils, eosinophils, and neutrophils) that may either positively or negatively affect the repair process. 45 The decision to include or exclude WBCs in PRP applications is a major point of controversy. Leukocytes have been associated with inflammatory cytokines (IL-1, TNF-alpha), which could have potentially deleterious effects on tissue regeneration. 75 However, a recent metaanalysis by Fitzpatrick et al 25 found that leukocyte-rich PRP, such as that in the GPS III system, had a significantly greater positive effect on tendon healing than leukocytepoor PRP. In this review, we observed various leukocyte concentrations in PRP formulations across studies, with 75.7% of studies not reporting leukocyte concentrations at all. This heterogeneity highlights a need to quantify and report WBC concentrations in future randomized controlled studies to standardize PRP treatments and increase comparability between studies. Overall, the effect of leukocytes in PRP is not well studied and warrants further investigation.
Platelet activation is another subject of extensive research, as the addition or exclusion of activation agents is likely to affect the efficacy of PRP. Activation has been suggested as a required process of PRP preparations, 11, 43, 92 but over half of the studies included in this review (51.4%) did not use any form of activation. A recent study comparing the different types of PRP activating agents found that PRP activated with CaCl 2 , thrombin, or CaCl 2 /thrombin combination had a significantly higher growth factor release compared with nonactivated PRP and platelet-poor plasma. This suggests that the underlying therapeutic efficacy of many current studies may be limited by their lack of activation usage. Additionally, different activating agents release different concentrations of growth factors over time. For example, the CaCl 2 /thrombin combination produced a higher growth factor release compared with CaCl 2 alone or type III collagen alone in the first hour, but CaCl 2 activation alone produced the highest growth factor release over a 24-hour period. Thus, both the compound used to activate PRP and the time between activation and application affect the overall PRP formulation. More work is needed to standardize the use of activating agents to determine the most effective method of activation, if any is needed at all.
Because we did not focus on a specific injury or anatomic region of the body, there is extensive heterogeneity in the studies. However, this review shows that even among studies investigating PRP for the same injury, there is a great deal of variability in the literature itself. For example, the rotator cuff was the only injury subgroup that showed significant heterogeneity at baseline. This heterogeneity may be attributable to different degrees of injury in patient populations, as the tear size ranged from 10 to 50 mm, which includes the broad spectrum of partial to large tears. 13 Another source of heterogeneity was the control treatment. For example, lateral epicondylitis studies used a variety of different control treatments, including betamethasone with lignocaine, saline, corticosteroid, bupivacaine, and whole blood. More data are needed to determine what factors may have contributed to heterogeneity in the lateral epicondylitis subgroup, as there was substantial heterogeneity reported in both short-term and long-term VAS scores for this injury.
The quantitative analysis conducted in this review has several limitations. To accommodate for the variability between studies and outcome measures, only studies that reported VAS scores were included in the quantitative analysis. While this allowed us to compare clinical efficacy across pathological conditions and include a large number of high-quality studies, it also meant that only 21 of the 37 studies included in this review could be analyzed quantitatively. Another limitation of our quantitative analysis is the VAS itself, which is generally less sensitive than injury-specific outcome measures. Additionally, VAS scores were compared as if they were identical, despite the fact that there was some variability in the way that scores were obtained. For example, numeric, nonnumeric, injury-specific (eg, VAS with the Neer test 38 ), and 100-point VAS scores were considered equivalent and converted to a nonspecific 10-point VAS score for quantitative analysis. Last, the quantitative analysis does not tell us whether PRP improves functional outcomes because the VAS only measures pain severity. While a number of studies did report functional outcomes, the heterogeneity of the pathological conditions and outcome measures precluded meaningful comparisons. Statistically significant pain reductions must also be interpreted with caution, as statistical significance does not necessarily imply clinically significant differences. Nevertheless, given the data available in the current literature, our analysis of VAS scores provides the most comprehensive evaluation of PRP's efficacy in pain reduction to date.
The lack of comparability between studies highlights the need for standardization in the way that outcomes are measured. The Patient-Reported Outcomes Measurement Information System (PROMIS) is a recently developed tool that may help address this problem. PROMIS scores have correlated well with current measurement instruments used in orthopaedic evaluations and may help address study heterogeneity, reduce bias, and increase comparability between studies. 33 For instance, a recent study by Anthony et al 4 found that both the PROMIS Upper Extremity and PROMIS Physical Function instruments had good to excellent correlations with common shoulder instability patient-reported outcome instruments, including the American Shoulder and Elbow Surgeons shoulder score and Short Form-36 Health Survey physical function subscale. Overbeek et al 58 found that the PROMIS Physical Function instrument moderately correlated with the Quick Disabilities of the Arm, Shoulder and Hand, suggesting that the new assessment tool may be used to measure upper extremity disability. The psychometrically validated dynamic system measures patient-reported outcomes efficiently in study participants with a wide range of chronic diseases and demographic characteristics by administering survey questions based on the respondent's previous answers. This computer adaptive testing provides precise measurements and eases the survey burden on patients by screening out irrelevant questions.
This review highlights a critical need for PRP characterization and standardization, but more research is also needed on tendon and ligament biology itself. Tendon and ligament regeneration has proved an elusive goal for tissue engineering, owing to the specialized nature of these tissues and the high mechanical demands placed on the extracellular matrix of these structures in the human body. 39 The mechanical environment affects the expression of extracellular matrix proteins, growth factors, transcription factors, and cytokines that can alter tendon structure and cell viability. 40 The particular biological properties of the tendon extracellular matrix have hindered attempts to promote regeneration, 39 and no agreement exists on the most optimal delivery method of in vivo growth factors. 56 More work is needed to clarify the effect of PRP on scar formation and on how to maximize PRP utilization, given the mechanical properties of tendons and ligaments. Future studies combining PRP and scaffold technology may help improve the structural performance of damaged and degenerated tissues but have not been well studied clinically. Studies have shown that, in tendon healing, scaffolds stimulate healing and protect the healing area from detrimental forces, thereby maintaining the integrity of the healing zone. 73 Examples of previously investigated scaffolding materials include hydrogel, collagen, polyglycolic acid, fibrin, chondrocytes, and combinations of these compounds. 41, 54, 66 Overall, there is a need to investigate the biochemical properties of each material and how they affect the mechanical properties of tendons and ligaments to draw reliable conclusions and meaningful comparisons between PRP formulations.
CONCLUSION
This systematic review and meta-analysis found evidence that suggests that PRP may provide both short-term and long-term pain relief for tendon and ligament injuries compared with alternative treatments. In particular, there was evidence that PRP is associated with less pain in rotator cuff injuries and lateral epicondylitis, but there was insufficient evidence to draw conclusions for all other injuries. While these findings are encouraging, the heterogeneous nature of the studies conducted to date and the failure to characterize the exact composition of the PRP ''drug'' limit definitive conclusions. According to our review, PRP is safe and may be efficacious. However, we cannot issue recommendations for or against its use until more homogeneous, high-quality evidence on the optimal preparation, dosage, and efficacy is made available. The greatest limiting factor for PRP is the lack of standardization. More research needs to be conducted to understand how leukocyte inclusion, activation, and platelet concentration affect therapeutic efficacy.
